Overall, our results potentially explain the clinical observation that HDACi treatment alone elicits limited anti-cancer activity in synovial sarcoma patients, and provide a biological rationale for blocking FYN function to improve HDACi action in synovial sarcoma treatment. The gene discussed is FYN; the disease is cancer.